Project Details
Description
A Phase 2, Sequential, Ascending Dose Study to Characterize the Safety, Tolerability, Pharmacokinetic and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)
| Status | Finished |
|---|---|
| Effective start/end date | 4/13/10 → 4/12/15 |
Funding
- CELGENE CORPORATION
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.